Paediatrics Search

Paediatrics

Paediatrics

Home News Diseases Conferences Special Reports Multimedia

ASTHMA (PEDIATRIC)

Asthma is a chronic inflammatory disease of the airways in the lungs of children and adults.
The patient usually complains of shortness of breath, chest tightness and coughing with wheezing.

A diagnosis of asthma in young children is more likely if they have symptom patterns, presence of risk factors for development of asthma and therapeutic response to controller treatment.
Goals of treatment are effective symptom control with minimal or no exacerbations, minimal or no nocturnal and daytime symptoms, no limitations on activities, minimal or no need for reliever treatment, and minimal adverse effects of medication.

Asthma%20(pediatric) Signs and Symptoms

Signs and Symptoms

Introduction

A heterogeneous disease with chronic inflammatory disorder of the airways
Most common chronic disease in pediatric age groups that causes significant morbidity
Characterized by history of respiratory symptoms (eg wheeze, shortness of breath, chest tightness and cough) that vary over time and in intensity, together with variable expiratory airflow limitation
Symptoms occur with exercise, laughing or crying in the absence of an apparent respiratory infection

Signs and Symptoms

Recurrent episodes

Wheezing
Breathlessness
Heavy breathing
Cough that is recurrent or persistent non-productive that may be worse at night
Chest tightness
Reduced activity

Combined Ag/Ab rapid testing boosts case-finding in COVID-19

Elvira Manzano, 29 Jul 2021

A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.

Product Highlight - Oncaspar

14 Sep 2023

Pegaspargase powder for solution for injection/infusion 3,750 units

Immunotherapy sparks hope for paediatric ALL

Audrey Abella, 14 Oct 2020

Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.